43 results on '"van Gelder, Michel"'
Search Results
2. Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?
3. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL
4. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial
5. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL
6. Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial
7. Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial
8. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
9. Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party
10. Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi‐state modeling.
11. Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study
12. Intensive treatment and trial participation in elderly acute myeloid leukemia patients: A population-based analysis in The Netherlands
13. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies
14. Clinical Practice Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) in The Netherlands
15. Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia
16. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties
17. Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT
18. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
19. Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT
20. Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societé Française de Greffe de Moelle et Therapie Cellulaire
21. Permitting patients to pay for participation in clinical trials: the advent of the P4 trial
22. Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer
23. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
24. Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A
25. Compartmentalization of Acyclovir-Resistant Varicella Zoster Virus: Implications for Sampling in Molecular Diagnostics
26. Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.
27. Elimination of the chemotherapy resistant subpopulation of 4T1 mouse breast cancer by haploidentical NK cells cures the vast majority of mice
28. Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: Lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study
29. Resolution of Waldenströmʼs macroglubulinemia related isolated neutropenia by immunochemotherapy
30. Real‐world experience: Introduction of T cell replete haploidentical transplantations in a single center.
31. Preserved organic anion transport in mutant TR- rats with a hepatobiliary secretion defect
32. The GLOW trial in chronic lymphocytic leukaemia.
33. Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia.
34. Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning.
35. Iron refractory iron deficiency anemia: a heterogeneous disease that is not always iron refractory.
36. Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society.
37. High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study.
38. Klebsiella pneumoniae-triggered DC recruit human NK cells in a CCR5-dependent manner leading to increased CCL19-responsiveness and activation of NK cells.
39. ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response.
40. TREATMENT OF RELAPSING EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS WITH LARGELY MHC-MATCHED ALLOGENEIC BONE MARROW TRANSPLANTATION1.
41. T-cell Large Granular Lymphocytic Leukaemia with an Uncommon Clinical and Immunological Phenotype.
42. Comparison of Allogeneic Stem Cell Transplantation and Non-Transplant Approaches in Elderly Patients with Advanced Myelodysplastic Syndrome: Optimal Statistical Approaches and a Critical Appraisal of Clinical Results Using Non-Randomized Data.
43. A New Method for Estimating Treatment-Related Mortality for Older Patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.